AbbVie's Experimental Therapy Shows Reduction in Type of Lung Cancer in Phase 2 Study
November 29 2023 - 10:12AM
Dow Jones News
By Colin Kellaher
AbbVie said Wednesday that a Phase 2 study of its experimental
drug telisotuzumab-vedotin, or teliso-V, showed a reduction in
disease in patients with a type of non-small cell lung cancer.
AbbVie said the study evaluating teliso-V in patients with c-Met
protein overexpression, epidermal growth factor receptor wild type,
advanced/metastatic nonsquamous non-small cell lung cancer showed a
reduction in the disease in 35% and 23% of c-Met High and c-Met
Intermediate patients, respectively.
In addition, the company said the study results showed that
patients' tumors continued to respond to treatment for a median
duration of nine months and 7.2 months across c-Met High and c-Met
Intermediate patients, respectively, with the patients surviving
for a median of 14.6 months and 14.2 months, respectively.
Lung cancer is the leading cause of cancer death around the
world, with non-small cell lung cancer accounting for about 85% of
all cases.
AbbVie said C-Met protein overexpression is found in about 25%
of advanced epidermal growth factor receptor wild type non-small
cell lung cancer patients and is associated with a poor
prognosis.
The North Chicago, Ill.-based biopharmaceutical company said it
plans to hold talks with global health authorities on the potential
to support an accelerated approval of teliso-V.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 29, 2023 09:57 ET (14:57 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2024 to Jun 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2023 to Jun 2024